Contact us

Welcome to
Shield Therapeutics

Find out about us

Our People

Driven by and committed to our goals

Our Investors

Delivering more value to our shareholders

Careers

Offering opportunity, ambition and development

Specialty pharmaceutical company

Providing solutions to unmet medical needs.

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.

Find out more

Our Products

A treatment for iron deficiency anaemia

Our lead product, Feraccru®, is a novel oral treatment for iron deficiency anaemia (IDA) which, following receipt of marketing authorisation in early 2016, is now commercially available for use initially in patients with inflammatory bowel disease
associated IDA.

Find out more

PM Society Awards Gold winner for Events & Exhibitions

Awarded Company of the Year at the 2016 Bionow Awards

28 Jun 2018

Shield reports recently presented supportive data from real-world…

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, today…

14 Jun 2018

Shield reports positive top-line results from its AEGIS-PAED…

STX_PK Paediatric Study_Final_14June18

5 Jun 2018

Shield Therapeutics plc Announces Directorate Change

For further details please see the press release below: STX_RNS Board Change
View more news articles